Sugammadex for our little ones: a brief narrative review
- Author:
Soomin LEE
1
;
Woosuk CHUNG
Author Information
- Publication Type:Review
- From:Anesthesia and Pain Medicine 2024;19(4):269-279
- CountryRepublic of Korea
- Language:English
- Abstract: Sugammadex, the first noncompetitive antagonist developed for the reversal of neuromuscular blockade (NMB), is one of the few drugs that has revolutionized anesthetic practice. However, the use of sugammadex for children between the ages of 2 and 17 years has only recently been approved and is currently not approved for children under the age of 2 years. Although the precision and reliability of reversal of NMB with sugammadex are of great benefit in pediatric anesthesia, several important questions remain regarding its use in our youngest patients. In this brief narrative review, we aim to provide an overview of the key considerations and potential challenges that anesthesiologists often face when using sugammadex in pediatric patients.
